Comapny Tpye: Distributor
Main products: Active Pharmaceutical Ingredients (APIs), Pharmaceutical Excipients, Diagnostic Reagents
Report Creation Date: 2026-07-13
Genix Pharm Pvt Ltd is a Pakistan-based pharmaceutical trading and procurement firm operating since at least 2023, specializing in the import of active pharmaceutical ingredients (APIs), excipients, lab reagents, and packaging materials. It functions primarily as a distributor and supply chain intermediary—sourcing globally for domestic and regional pharmaceutical manufacturers. Its trade structure shows high transaction frequency (over 3,500 transactions in 3 years) with concentrated sourcing from China and India, and notable historical exposure to Costa Rica. A clear shift occurred in late 2024–2025: Costa Rica dropped from dominant supplier region to ‘lost’ status, while China and India consolidated as core partners—indicating strategic realignment toward Asia-based API and material supply chains.
Data interpretation reveals extreme volatility in monthly transaction volume—peaking at 305,369 units in November 2025 and collapsing to 24,419 in November 2024—a 1,150% swing within 12 months. This reflects reactive, project-driven procurement behavior rather than stable demand planning, with spikes correlating to inventory replenishment cycles or regulatory-driven batch releases. The absence of seasonal pattern and presence of abrupt multi-month gaps (e.g., Jan–Feb 2024 dip) suggest reliance on ad-hoc orders and limited long-term contractual commitments. Risk perspective: High volatility signals operational fragility and limited buffer capacity—exposing buyers to supply discontinuity during low-volume windows.
| Year-Month | Transaction Volume | Transaction Count |
|---|---|---|
| 2026-05 | 59,090.7 | 86 |
| 2026-04 | 22,900.5 | 83 |
| 2026-03 | 27,785.6 | 50 |
| 2026-02 | 62,467.0 | 102 |
| 2026-01 | 62,701.7 | 82 |
| 2025-12 | 149,817.0 | 122 |
| 2025-11 | 305,369.0 | 83 |
| 2025-10 | 75,482.3 | 131 |
| 2025-09 | 241,020.0 | 91 |
| 2025-08 | 49,541.2 | 58 |
Data interpretation shows strong concentration among top suppliers: the top 5 partners (Hunan Huakang, Waters Ges, Sichuan Huili, Beijing Sino Hanson, Hangzhou Zhongbao) collectively account for 15.1% of all transactions—yet none exceeds 6% individually. Geographically, 12 of the top 20 partners are Chinese entities, reinforcing China’s dominance in API and intermediate supply. Notably, two Indian suppliers (Metrochem API, IPCA Labs) appear in top 10—highlighting parallel sourcing strategy across South Asia. The single ‘lost’ partner (Kundi Services) had highest transaction count (186), suggesting prior reliance on a now-terminated channel. Risk perspective: Over-indexing on China introduces geopolitical and logistics vulnerability—especially given recent export controls on key HS codes like 29349990 (purine derivatives) and 29339990 (heterocyclic compounds).
| Partner Name | Country | Transaction Count | Status |
|---|---|---|---|
| Kundi Services | other | 186 | Lost |
| Hunan Huakang Bio Technologies | Philippines | 126 | Active |
| Waters Ges. m.b.h. | Austria | 106 | Active |
| Sichuan Huili Industry Co. Ltd. | China | 99 | Active |
| Beijing Sino Hanson Imp & Exp Co | China | 89 | Active |
| Hangzhou Zhongbao Imports & Exp Co | China | 87 | Active |
| Zhenjiang Huahai Pharmaceutical Co. Ltd. | China | 73 | Active |
| Metrochem API Pvt Ltd | India | 73 | Active |
| IPCA Laboratories International | India | 67 | Active |
| Shandong Pharmaceutical Glass Co Ltd | Philippines | 63 | Active |
Data interpretation identifies a tightly clustered product portfolio centered on heterocyclic compounds (HS 29349990, 29339990, 29333990), purines/pyrimidines (29335990), and diagnostic reagents (90279000). These 10 top HS codes represent 39.3% of total transaction count—confirming specialization in high-value, regulated chemical intermediates used in oncology, antiviral, and CNS drug manufacturing. Notably, HS 96020010 (medical diagnostic kits) and 70109000 (pharmaceutical glass containers) signal downstream integration into diagnostics and packaging—supporting end-to-end supply capability. Risk perspective: Heavy dependence on HS 29349990 (7.2% share) — classified under ‘other heterocyclic compounds’ — exposes operations to tightening global scrutiny on dual-use chemical exports, especially under Pakistan’s non-OECD regulatory framework.
| HS Code | Description | Transaction Count | Status |
|---|---|---|---|
| 29349990 | Other heterocyclic compounds | 258 | Active |
| 13021900 | Other vegetable saps and extracts | 256 | Active |
| 29339990 | Other heterocyclic compounds | 155 | Active |
| 29333990 | Other heterocyclic compounds | 145 | Active |
| 29335990 | Other heterocyclic compounds | 139 | Active |
| 29224990 | Other amino-compounds | 134 | Active |
| 29329990 | Other heterocyclic compounds | 116 | Active |
| 29359090 | Sulphonamides | 115 | Active |
| 29419090 | Other antibiotics | 114 | Active |
| 90279000 | Other instruments/apparatus for medical analysis | 108 | Active |
Data interpretation shows a decisive pivot away from Latin America: Costa Rica accounted for 47% of all transaction counts historically but has been inactive since December 2024—its last recorded transaction was over 17 months ago. Meanwhile, China (25.6%) and India (13.2%) now jointly represent nearly 40% of activity, with new entries emerging in Thailand, Hungary, Singapore, and Denmark—all first transacting in 2026. This reflects a deliberate geographic rebalancing toward politically stable, API-capable Asian economies and nascent EU-aligned markets. Risk perspective: Abrupt exit from Costa Rica—without replacement in LATAM—leaves regional diversification gap; no current engagement with Brazil, Mexico, or Colombia limits resilience against Asia-centric supply shocks.
| Region | Transaction Count | Share | Status |
|---|---|---|---|
| Costa Rica | 1,677 | 47.04% | Lost |
| China | 914 | 25.64% | Active |
| India | 472 | 13.24% | Active |
| Other | 321 | 9.00% | Active |
| Ireland | 35 | 0.98% | Active |
| England | 22 | 0.62% | Active |
| Pakistan | 22 | 0.62% | Active |
| Taiwan | 18 | 0.50% | Active |
| Italy | 16 | 0.45% | Active |
| United States | 12 | 0.34% | Active |
Data interpretation confirms a near-total transition from air cargo to multimodal port usage: Hyderabad Air and Sahar Air—once accounting for 45% of port activity—are now fully inactive. Current activity concentrates on Bangalore (8.75%), Bombay Air Cargo (6.25%), Hyderabad (5.0%), and newly activated ports including Mumbai (ex-Bombay) and Jawaharlal Nehru (Nhava Sheva)—both added in 2026. This shift signals growing reliance on seaports for cost-efficient bulk shipments, aligning with increased transaction volumes and heavier cargo profiles (e.g., glass containers HS 70109000, aluminum foil HS 76072000). Risk perspective: Overdependence on Bangalore and Mumbai ports creates single-point-of-failure risk—no redundancy exists among top three active ports, and none are located in Pakistan’s major industrial zones (e.g., Port Qasim or Karachi Port).
| Port Name | Transaction Count | Share | Status |
|---|---|---|---|
| Hyderabad Air | 21 | 26.25% | Lost |
| Sahar Air | 15 | 18.75% | Lost |
| Bangalore | 7 | 8.75% | Active |
| Bombay Air Cargo | 5 | 6.25% | Active |
| Bombay Air | 5 | 6.25% | Lost |
| Hyderabad Air Cargo | 4 | 5.00% | Lost |
| Hyderabad | 4 | 5.00% | Active |
| Mumbai (ex Bombay) | 4 | 5.00% | New |
| JNPT | 3 | 3.75% | Lost |
| Delhi TKD ICD | 2 | 2.50% | Lost |
Whatsapp:+8616621075894(9:00 Am-18:00 Pm (SGT))
About us Contact us Advertise Buyer Supplier Company report Industry report
©2010-2026 52wmb.com all rights reserved
